Endocrine Abstracts

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

Introduction: Therapeutic durability of GLP1-based therapies in patients with type 2 diabetes mellitus (T2D) is incompletely understood. Our aim was to explore the therapeutic effects of GLP1 based therapies in patients with T2D.Methods: This was a retrospective study on patients with T2D (n=55) who attend a specialist clinic at UHCW, Coventry, and who had been treated with the GLP1 based therapy, Liraglutide, for at least 6 months. A successful...